Novotech expands IT infrastructure in Asia-Pacific region with launch of Oracle trial service

asia pacific globe
Novotech adds Oracle’s Trial Management and Monitoring Cloud Service to support its work in the Asia-Pacific region. (blackred iStock)

Australia’s Novotech added to its IT infrastructure investment by launching Oracle’s Trial Management and Monitoring Cloud Service (TMMCS) to support its work in the Asia-Pacific region.

It is the largest implementation of TMMCS in that region, and Novotech becomes the first biotech-focused CRO in Asia-Pacific to use the technology.

TMMCS provides a real-time look into clinical trial progress and significant utilization rates of clinic and staff resources that helps lower costs while increasing speed and data quality, the company said. The technology also ensures regulatory compliance, integration with global studies and gives clinic staff and clients better data visibility.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Oracle’s cloud technology provides a centralized trial database enabling improved access, control and governance of clinical data,” John Moller, M.D., Novotech’s chief executive, said in a statement. “The system is highly configurable allowing us to tailor process flows and alerts to client needs, as well as ensuring effective control on deviation.”

The CRO, which has seen a very busy year with the additions of new partners and clinics, now has 10 strategic collaborations with hospitals and research institutions across the Asia-Pacific region.

Suggested Articles

Scott Gottlieb has slipped right back into his old ways, becoming "special partner" at his old life science VC firm New Enterprise Associates.

Novartis, Otsuka, Pfizer and Sanofi will use technology from Verily’s Project Baseline to carry out clinical studies in various disease areas.

Biotech-CRO hybrid Evotec is continuing its buying and collaborating strategy with its acquisition of U.S. biologics company Just Biotherapeutics.